SLC16A8: A Promising Drug Target and Biomarker for Proton-Coupled Monocarboxylate Transporter 3

Target Name: SLC16A8

NCBI ID: G23539

SLC16A8

SLC16A8: A Promising Drug Target and Biomarker for Proton-Coupled Monocarboxylate Transporter 3

Introduction

Proton-coupled monocarboxylate transporter 3 (PCM3) is a protein that plays a crucial role in the regulation of intracellular acidification and buffering. It is a member of the subfamily of ATP-binding transport proteins (SMRTs), which are known for their ability to Transport nucleotides and other small molecules across cell membranes. PCM3 is expressed in various cell types and is involved in the intracellular acidification and buffering processes that maintain the proper pH of the cell environment, which is essential for the proper function of many cellular processes.

SLC16A8, a member of the SLC gene family, is a protein that belongs to the subfamily of ANOMEROSLC (AQP) proteins. These proteins are characterized by the presence of an N-terminal transmembrane region, a cytoplasmic region, and a C-terminal region that includes a putative anion transport mechanism. SLC16A8 is primarily expressed in the brain and is involved in the regulation of the intracellular acidification and buffering processes.

SLC16A8 functions as a PCM3-like protein that is involved in the regulation of intracellular acidification and buffering. It is a critical regulator of the pH of the cell environment and is involved in the maintenance of the proper pH for the proper function of many cellular processes . SLC16A8 is expressed in various cell types, including the brain, and is involved in the regulation of the intracellular acidification and buffering processes that are essential for the proper function of many cellular processes.

Drugs that target PCM3 have the potential to treat a wide range of diseases, including neurodegenerative disorders, pain, and psychiatric disorders. SLC16A8 is a promising drug target and biomarker for PCM3, as it is involved in the regulation of the intracellular acidification and buffering processes that are essential for the proper function of many cellular processes.

SLC16A8 Expression and Regulation

SLC16A8 is expressed in various cell types, including the brain, and is involved in the regulation of the intracellular acidification and buffering processes. It is a critical regulator of the pH of the cell environment and is involved in the maintenance of the proper pH for the SLC16A8 is expressed in a variety of cell types, including the brain, heart, and lens, and is involved in the regulation of the intracellular acidification and buffering processes that are essential for the proper function of many cellular processes..

SLC16A8 is regulated by various signaling pathways, including the TGF-β pathway and the Wnt pathway. These signaling pathways are involved in the regulation of cell growth, differentiation, and survival, and are critical for the proper function of many cellular processes. SLC16A8 is also regulated by various co-regulators, including Nrf2, AP-1, and NF-kappa-B. These co-regulators are involved in the regulation of various cellular processes, including DNA damage repair, cell signaling, and inflammation.

SLC16A8 Interactions with Other Proteins

SLC16A8 is involved in the regulation of intracellular acidification and buffering processes, and it interacts with various proteins that are involved in these processes. One of the key interactions of SLC16A8 is with PCM3, the protein that it is substituted. SLC16A8 is involved in the regulation of the intracellular acidification and buffering processes that are

Protein Name: Solute Carrier Family 16 Member 8

Functions: Probable retinal pigment epithelium (RPE)-specific proton-coupled L-lactate transporter (By similarity). May facilitate transport of lactate and H(+) out of the retina and could therefore play a role in pH and ion homeostasis of the outer retina (By similarity)

The "SLC16A8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets